Clinical Trial Update: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating GD2-targeted CAR T-cells engineered with IL-15 and inducible caspase-9 for relapsed/refractory neuroblastoma or osteosarcoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Osteosarcoma

Drugs mentioned

• GD2-targeted CAR T-cell therapy with IL-15 and inducible Caspase-9

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Neuroblastoma, Osteosarcoma | Phase 1 | Status: RECRUITING